Search
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44161] Men are most likely to experience symptomatic illness due to the X-linked provenance of the disorder. … [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801]
Nateglinide
go.drugbank.com/drugs/DB00731ApprovedThe average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.
Synonyms: DB-OTOTaurine
go.drugbank.com/drugs/DB01956ApprovedInvestigationalNutraceutical[A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat. … [L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label]
Pramlintide
go.drugbank.com/drugs/DB01278ApprovedInvestigationalPramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals.
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigational[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position … of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
Clascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[A218771] By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland … It binds to androgen receptors with high affinity.
Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalTwo denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.
Irinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigational[A263376] Approved by the FDA in 1996,[A263366] irinotecan is used to treat colorectal cancer and pancreatic adenocarcinoma. … This leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376]